Zampilimab, also known as UCB-7858 or 2098280-42-1, represents a innovative therapeutic molecule targeting TGM2, a protein involved in fat metabolism and conceivably implicated in various inflammatory disorders. This engineered antibody demonstrates considerable potential in laboratory evaluations,

Penpulimab, identified by the distinct CAS number 2350298-92-7, represents a emerging clinical antibody currently undergoing assessment for its potential in tumor treatment. This biologic agent is designed to target a defined process involved in neoplastic growth. Early information suggest it exhibi

Datopotamab Deruxtecan, often abbreviated as DATO, represents an important advancement within targeted cancer therapy. This novel antibody-drug conjugate pairs an monoclonal antibody specifically targeting HER2 positive expressing cells with the potent chemotherapeutic payload, deruxtecan. The proce